Cargando…
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
The pharmaceutical inactivation of driver oncogenes has revolutionized the treatment of cancer, replacing cytotoxic chemotherapeutic approaches with kinase inhibitor therapies for many types of cancers. This approach has not yet been realized for the treatment of HER2-amplified cancers. The monother...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Association for Cancer Research
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379361/ https://www.ncbi.nlm.nih.gov/pubmed/35731927 http://dx.doi.org/10.1158/0008-5472.CAN-22-1121 |